Todd Davis
About Todd Davis
Todd Davis serves as the Chief Executive Officer and Director at Virocell Biologics and Ligand Pharmaceuticals, bringing over 30 years of operational and investment experience in the healthcare sector. He has played a significant role in healthcare financings exceeding $4 billion and has co-founded multiple firms, including HealthCare Royalty Partners.
Current Role at Virocell Biologics
Todd Davis serves as the Director at Virocell Biologics, a position he has held since 2021. In this role, he contributes to the strategic direction and operational management of the company, leveraging his extensive experience in the healthcare and biopharmaceutical sectors.
Leadership at Ligand Pharmaceuticals
Since 2022, Todd Davis has held the title of Chief Executive Officer and Director at Ligand Pharmaceuticals. His leadership is focused on driving the company's growth and innovation in the biopharmaceutical industry, building on his previous experience as a Director at Ligand from 2007 to 2022.
Education and Expertise
Todd Davis holds a Bachelor of Science degree from the United States Naval Academy, where he studied from 1979 to 1983. He also earned a Master of Business Administration (MBA) from Harvard Business School, completing his studies from 1995 to 1997. His educational background supports his extensive operational and investment experience in the healthcare sector.
Professional Background
Todd Davis has over 30 years of operational and investment experience in the healthcare industry. He began his career in sales at Abbott Laboratories and has held various leadership roles, including Founder and Managing Partner of HealthCare Royalty Partners. He has also served as a partner at Paul Capital Partners and Apax Partners, focusing on biopharmaceutical investments.
Achievements in Healthcare Financing
Throughout his career, Todd Davis has been involved in over $4 billion in healthcare financings, including growth equity and structured debt. He has co-founded Healthcare Royalty Partners and Royalty Rx Capital, and has led numerous IP licenses and royalty-debt deals, demonstrating his expertise in the biopharmaceutical financing landscape.